No change of sleep after 6 and 12 months of methadone maintenance treatment.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 21769060.
- Also identified by DOI 10.1097/ADM.0b013e3181e8b6c4.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To determine whether the methadone maintenance treatment (MMT) affects sleep. We prospectively followed up the sleep pattern of 23 opiate addicts when admitted to MMT and after 6 and 12 months of treatment. Pittsburgh Sleep Quality Index, pain self-report questionnaires, urine for drug abuse, and one-night sleep polysomnography were assessed. The baseline sleep indices (sleep time [5.5 ± 1.1 hours], sleep efficiency [80.6% ± 10.5%], rapid eye movement [REM] stage percent of sleep [14.3% ± 8.4%], percent of non-REM stage 3-4 [6.7% ± 8.6%], and Pittsburgh Sleep Quality Index Scores [11.4 ± 4.8]) did not change at 6 and 12 months. Proportion of patients with absent non-REM stage 3-4 reduced (47.8%, 34.8%, 13%, P = 0.03), and mean REM density increased (P = 0.04). Body mass index increased (24 ± 4.2 kg/m, 25.7 ± 4 kg/m, 27.1 ± 4.8 kg/m, P < 0.0005) with no change in the rate of benzodiazepine abuse or chronic pain. No patient had central sleep apnea. The Respiratory Disturbance Index (apnea or hypopnea numbers/sleep hr) increased among 5 patients who increased ≥25% of their entry weight (3.4 ± 4.1, 11.8 ± 10.1, 29.6 ± 30.4 Respiratory Disturbance Index's) but not with the other 18 (3.9 ± 4.8, 6.2 ± 6.2, 7.8 ± 7.4). We conclude that MMT did not negatively affect the opiate addicts' baseline poor perceived and objective sleep. Only extensive weight gain (evident in a minority of patients) was associated with obstructive sleep apnea.
Medical subject headings
- Analgesics, Opioid
- Methadone
- Opioid-Related Disorders
- Sleep